BDNF and Alzheimer disease: Open‐label Phase I clinical trial of AAV2‐BDNF gene therapy is ongoing to assess the safety, tolerability, and preliminary efficacy of AAV2‐BDNF stereotaxic brain injection in early AD and Mild Cognitive Impairment (MCI).